John Young - Director | Johnson Controls International (JCI) Executive Profile & Compensation

About John D. Young

Independent director of Johnson Controls International plc; age 60; director since December 2017. Retired Chief Business Officer of Pfizer Inc. (2019–2021), then Special Advisor to the CEO until retirement in July 2022; previously led multiple global business units at Pfizer (Group President roles across Innovative Health, Essential Health, Global Established Pharma, and Primary Care) . Serves on the Compensation & Talent Development Committee; the Board classifies him as independent under its stricter-than-NYSE standards . Other current public boards: Arvinas, Inc. and Novartis AG .

Past Roles

Organization	Role	Tenure	Committees/Impact
Pfizer Inc.	Chief Business Officer	Jan 2019 – Dec 2021	Senior leadership over corporate business development and portfolio; corporate ESG oversight via Pfizer Foundation board
Pfizer Inc.	Special Advisor to the CEO	Jan 2022 – Jul 2022	Strategic advisory during transition to retirement
Pfizer Inc.	Group President, Innovative Health	2018	Led innovative medicines business globally
Pfizer Inc.	Group President, Essential Health	2016 – 2018	Led established medicines portfolio worldwide
Pfizer Inc.	Group President, Global Established Pharma	2014 – 2016	Ran global established product franchise
Pfizer Inc.	President & GM, Primary Care; Regional President Europe/Canada; UK Country Manager	2007 – 2013; 2009 – 2012; 2007 – 2009	Commercial leadership across geographies/business units

External Roles

Organization	Role	Tenure	Committees/Impact
Novartis AG	Director	Current	Multinational pharma board; committee roles not disclosed
Arvinas, Inc.	Director	Current	Clinical-stage biopharma board; committee roles not disclosed

Board Governance

Committee membership: Compensation & Talent Development Committee (members: Archer, Decker, Vergnano—Chair, Young); held 4 meetings in FY2024; all members independent and qualify as “outside” directors under Section 162(m) .
Independence: Board determined Young meets stringent independence criteria; 11 of 12 director nominees are independent .
Attendance: In FY2024, the Board met 8 times; all directors attended at least 75% of Board/committee meetings; average attendance ≈99%; directors are expected to attend the AGM and did so in 2024 .
Executive sessions: Independent directors regularly meet in executive session, led by the Lead Independent Director .

Committee	Role	FY2024 Meetings
Compensation & Talent Development	Member	4

Fixed Compensation

Component	Amount	Notes
Annual cash retainer	$145,000	Standard non-employee director retainer
Committee chair fee	$0	Not a chair; chairs receive $25,000
Lead Director fee	$0	Lead Director receives $40,000; not applicable to Young
Total cash fees (FY2024)	$145,000	As reported in the director compensation table

Performance Compensation

Component	Grant Date Value	Vesting	Metrics/Structure
RSUs (annual grant)	$180,000	One-year vest; units convert to shares at vest	Time-based RSUs; no performance conditions disclosed for directors
Options	—	—	No option awards disclosed for directors
Equity grant timing policy	—	—	Company maintains standardized grant schedules to avoid market timing; annual awards generally on first business day of December

Other Directorships & Interlocks

External Board	Role	Interlock/Transaction Exposure
Novartis AG	Director	Company policy requires review/approval of director outside boards; related-party transactions must be pre-approved and are limited; JCI’s commercial dealings with companies employing its directors did not exceed 1% of JCI gross revenues and are not considered related-party transactions
Arvinas, Inc.	Director	Same policy framework; no disclosable related-person transactions above SEC $120,000 threshold or 1% revenue test tied to directors noted

Expertise & Qualifications

30+ years of healthcare leadership at Pfizer; experienced in technology-driven healthcare solutions and large business unit management .
Corporate social responsibility and ESG oversight experience via Pfizer Foundation and ESG commitments; global executive roles across regions .

Equity Ownership

Holder	Shares Beneficially Owned	% of Outstanding	Notes
John D. Young	12,964	<1%	As of Jan 7, 2025; 660,139,188 shares outstanding
Director ownership guideline	5× annual cash retainer	—	Directors expected to reach guideline within five years; guideline aims to align interests
Hedging/pledging	Prohibited	—	Company policy forbids pledging, hedging, short sales, and derivative monetization of JCI stock

Governance Assessment

Independence and workload: Young meets JCI’s enhanced independence standard and holds two external public boards (policy limit for non-executive directors is three), suggesting manageable outside commitments and low risk of time/attention conflicts .
Committee influence: As an active member of the Compensation & Talent Development Committee (4 meetings in FY2024; uses independent consultants per company policy), he participates in CEO succession, talent pipeline, and pay design—areas material to investor confidence .
Attendance and engagement: Board-level attendance metrics (8 meetings; average ≈99%; minimum ≥75%) indicate strong engagement norms; independent directors hold regular executive sessions, supporting effective oversight .
Alignment and incentives: Director pay mix balances cash ($145k) and equity ($180k RSUs; one-year vest) with robust share ownership guidelines (5× retainer) and strict anti-hedging/pledging policies, reducing misalignment and reputational risk .
Conflicts/related-party exposure: JCI’s pre-approval thresholds and reported absence of transactions exceeding 1% of revenue involving companies tied to directors mitigate conflict risk; no compensation committee interlocks or insider participation issues disclosed .

RED FLAGS: None disclosed specific to Young. Company-wide prohibitions on pledging/hedging and pre-approval of related-party transactions reduce alignment/conflict concerns; no low attendance or director-specific pay anomalies identified for Young .